By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – French molecular diagnostics outfit IntegraGen, the French National Institute for Health and Medical Research (INSERM), and its technology transfer subsidiary, INSERM Transfert, announced on Tuesday an agreement granting IntegraGen an exclusive worldwide option to license a portfolio of biomarkers for hepatocellular carcinoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.